Krystal Biotech (NASDAQ:KRYS) Sets New 52-Week High After Better-Than-Expected Earnings

Key Points

• Earnings beat and market reaction: Krystal reported Q1 EPS of $1.83 vs. $1.45 expected and revenue of $116.36M, sending the stock to a new 52-week high (intraday high $303.00) on strong volume.
• Commercial progress and cash runway: Revenue was driven by VYJUVEK sales (~$116.4M), the company completed enrollment in KB803 with registrational readouts on track for 2026, and it holds roughly $1.0B in cash to fund upcoming milestones.
• Analyst support but rich valuation and insider selling: Most analysts rate the stock a Buy with an average target around $323, yet the shares trade at a high P/E (~43), and insiders have sold about 129,164 shares in the last 90 days.

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report)'s stock price reached a new 52-week high on Tuesday following a stronger than expected earnings report. The stock traded as high as $303.00 and last traded at $292.3520, with a volume of 123047 shares trading hands. The stock had previously closed at $286.95.

The company reported $1.83 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. The business had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million.

Key Headlines Impacting Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Q1 beat — Krystal reported $1.83 EPS vs. $1.45 expected and $116.4M in revenue, driven by VYJUVEK sales and delivering strong margins that support profitability momentum. Zacks: KRYS Tops Q1
• Positive Sentiment: Operational and pipeline progress — company press release: $116.4M VYJUVEK global revenue, enrollment complete in KB803 (DEB corneal study), on track for KB803 and KB801 registrational readouts in 2026, and FDA platform technology designation for KB407 and KB111; strong cash balance (~$1.0B) supports upcoming milestones. Press Release
• Positive Sentiment: Analyst support — HC Wainwright raised Q2–Q4 2026 EPS forecasts (Q2 to $1.59, Q3 to $1.74, Q4 to $1.74) and reiterated a Buy with a $310 price target, signaling confidence in near‑term earnings power and leaving room for additional upside. (Coverage note reported by MarketBeat/Benzinga)
• Positive Sentiment: Market reaction and momentum — multiple outlets noted the stock’s rise after the earnings release and call as investors price in product revenue growth and upcoming data readouts as key catalysts. Investing.com
• Neutral Sentiment: Earnings call and detail flow — full call transcript and summaries are available for deeper review of commercial cadence, international rollout and R&D timelines; useful for modeling but no new guidance was issued. Earnings Call Transcript
• Neutral Sentiment: Valuation note — the stock trades at a relatively rich multiple (PE ~42.8) reflecting high growth expectations; this raises sensitivity to any delays or mixed clinical readouts. (Background metric investors should consider.)

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Wolfe Research assumed coverage on shares of Krystal Biotech in a research report on Friday, March 27th. They issued a "peer perform" rating for the company. Guggenheim raised their price objective on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Jefferies Financial Group raised their price objective on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a "buy" rating in a research report on Tuesday, February 17th. HC Wainwright restated a "buy" rating and issued a $310.00 price objective on shares of Krystal Biotech in a research report on Monday. Finally, The Goldman Sachs Group increased their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a "buy" rating in a report on Friday, January 30th. Ten investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $323.33.

Insider Activity at Krystal Biotech

In other news, Director Daniel Janney sold 37,895 shares of the firm's stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $266.88, for a total transaction of $10,113,417.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $263.21, for a total value of $6,580,250.00. Following the completion of the transaction, the insider owned 1,403,155 shares of the company's stock, valued at $369,324,427.55. This trade represents a 1.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 129,164 shares of company stock valued at $34,538,578. 13.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Krystal Biotech

Institutional investors have recently made changes to their positions in the stock. UMB Bank n.a. increased its position in shares of Krystal Biotech by 34.6% in the 4th quarter. UMB Bank n.a. now owns 144 shares of the company's stock worth $36,000 after purchasing an additional 37 shares during the last quarter. Optimize Financial Inc grew its position in shares of Krystal Biotech by 1.4% during the 4th quarter. Optimize Financial Inc now owns 2,855 shares of the company's stock valued at $704,000 after buying an additional 40 shares during the last quarter. Perigon Wealth Management LLC grew its position in shares of Krystal Biotech by 0.5% during the 4th quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company's stock valued at $2,211,000 after buying an additional 41 shares during the last quarter. Regal Investment Advisors LLC grew its position in shares of Krystal Biotech by 1.0% during the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company's stock valued at $1,075,000 after buying an additional 44 shares during the last quarter. Finally, Torray Investment Partners LLC grew its position in shares of Krystal Biotech by 0.4% during the 1st quarter. Torray Investment Partners LLC now owns 12,032 shares of the company's stock valued at $3,108,000 after buying an additional 47 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Trading Up 1.4%

The firm has a market cap of $8.56 billion, a P/E ratio of 42.95 and a beta of 0.50. The business's 50-day moving average is $261.72 and its two-hundred day moving average is $246.50.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.